Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1218789-33-3 | MDL No. : | MFCD07375178 |
Formula : | C13H20BN3O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QNCUDGRKLRQDMW-UHFFFAOYSA-N |
M.W : | 261.13 | Pubchem ID : | 46739651 |
Synonyms : |
|
Num. heavy atoms : | 19 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.69 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 75.31 |
TPSA : | 56.27 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -6.43 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 2.06 |
Log Po/w (WLOGP) : | 1.1 |
Log Po/w (MLOGP) : | 0.54 |
Log Po/w (SILICOS-IT) : | 0.95 |
Consensus Log Po/w : | 0.93 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.79 |
Solubility : | 0.421 mg/ml ; 0.00161 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.87 |
Solubility : | 0.352 mg/ml ; 0.00135 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.91 |
Solubility : | 0.0324 mg/ml ; 0.000124 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.01 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501 | UN#: | |
Hazard Statements: | H302-H312-H332 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
13% | With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); tricyclohexylphosphine In 1,4-dioxane at 100℃; for 16h; Inert atmosphere; Sealed tube; | 20.C Step C: 1 -(3 -(2-(cyclopropylamino)pyrimidin-5 -yl)-4-methyl- 1 -phenyl- 1 Hpyrazol-5-vl)-3-((3 S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea L005731 Step C: 1 -(3 -(2-(cyclopropylamino)pyrimidin-5 -yl)-4-methyl- 1 -phenyl- 1 Hpyrazol-5-vl)-3-((3 S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea: 1- (3-Bromo-4-methyl- 1 -phenyl- 1 H-pyrazol-5-yl)-3-((3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2- methoxyethyl) pyrrolidin-3-yl)urea (100 mg, 0.19 mmol), N-cyclopropyl-5-(4,4,5,5- tetramethyl- 1,3 ,2-dioxaborolan-2-yl)pyrimidin-2-amine (147 mg, 0.56 mmol) and tricyclohexyl phosphine (11 mg, 0.04 mmol) were combined in 1,4-dioxanes (3 mL) and purged with Argon for 5 minutes. Pd2ba3 (17 mg, 0.02 mmol) and K3P04 (432 jiL, 1.3M, 0.56 mmol) were added and the mixture purged with Argon for a further 30 seconds then sealed and stirred at 100 °C for 16 hours. The cooled mixture was filtered and the filtrate was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (2 x 10 mE) and the combined organic phases were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5-5% MeOHJDCM, then triturated with DCM, filtered and the filtrate concentrated to afford the title compound (14 mg, 13% yield) as a pale yellow solid. MS (apci) mlz = 589.3 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
27% | With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In water; dimethyl sulfoxide at 110℃; for 1.5h; Microwave irradiation; | 118A Example 118A N-alpha-[(trans-4-[(tert-Butoxycarbonyl)amino]methyl}cyclohexyl)carbonyl]-3-[2-(cyclopropylamino)pyrimidin-5-yl]-N-[4-(1H-tetrazol-5-yl)phenyl]-L-phenylalaninamide Example 118A N-alpha-[(trans-4-[(tert-Butoxycarbonyl)amino]methyl}cyclohexyl)carbonyl]-3-[2-(cyclopropylamino)pyrimidin-5-yl]-N-[4-(1H-tetrazol-5-yl)phenyl]-L-phenylalaninamide 3-Bromo-N-alpha-[(trans-4-[(tert-butoxycarbonyl)amino]methyl}cyclohexyl)carbonyl]-N-[4-(1H-tetrazol-5-yl)phenyl]-L-phenylalaninamide (150 mg, 0.24 mmol) and N-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2-amine (94 mg, 0.36 mmol) were dissolved in dimethyl sulphoxide (2 ml), and tetrakis(triphenylphosphine)palladium(0) (28 mg, 24 μmol), sodium carbonate (76 mg, 0.72 mmol) and water (0.36 ml, 20 mmol) were added. The reaction mixture was stirred at 110° C. in a microwave (Biotage Initiator) for 90 min, cooled, filtered and purified by chromatography via HPLC (Method 10). This gave 44 mg (27% of theory) of the title compound. LC-MS (Method 4): Rt=1.11 min; MS (ESIpos): m/z=681.4 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium fluoride; bis(tri-t-butylphosphine)palladium(0) In N,N-dimethyl-formamide at 100℃; for 2h; Molecular sieve; Inert atmosphere; | 299 2-(2-Chlorophenyl)-N-{4-[2-(cyclopropylamino)pyrimidin-5-yl]-3- sulfamoylphenyl}acetamide DMF was dried over molecular sieves and purged with argon. Then N-(4-bromo-3- [(dimethylamino)methylidene]sulfamoyl}phenyl)-2-(2-chlorophenyl)acetamide hydrochloride (1:1) (250 mg, 505 pmol), N-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrimidin-2-amine (264 mg, 1.01 mmol) and potassium fluoride (64.5 mg, 1.11 mmol) were dissolved in dry and degased DMF (7.7 ml) and the solution waspurged again with argon for 5 minutes followed by addition of bis(tri-tertbutylphosphine)palladium(0) (CAS 53199-31-8) (12.9 mg, 25.2 pmol) and the solution was purged again with argon. The reaction was heated for 2h at 10000. Afterwards the mixture was filtered over Celite, the solvent was removed under reduced pressure and the crude was used without further purification in the next step. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: potassium fluoride; bis(tri-t-butylphosphine)palladium(0) / N,N-dimethyl-formamide / 2 h / 100 °C / Molecular sieve; Inert atmosphere 2: ammonium hydroxide / methanol / 4 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With bis-triphenylphosphine-palladium(II) chloride; potassium acetate In 1,4-dioxane at 80℃; Inert atmosphere; Sealed tube; | 322.4 Step 4: N-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine A mixture of 5-bromo-N-cyclopropyl-pyrimidin-2-amine (600 mg, 2.8 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.1 g, 4.2 mmol), potassium acetate (550 mg, 5.6 mmol) and PdCl2(PPh3)2(393 mg, 0.56 mmol) in 1,4-dioxane (20 mL) under a nitrogen atmosphere was stirred overnight at 80° C. in a sealed tube. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography to afford the title compound as a yellow solid. LCMS (M+H)+ 180 (M-pinacol). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
22% | With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,4-dioxane; water at 80℃; for 2.5h; Inert atmosphere; Sealed tube; | 322.5 Step 5: 2-chloro-6-[4-[4-[2-(cyclopropylamino)pyrimidin-5-yl]-1-methyl-6-oxo-3-pyridyl]pyrazol-1-yl]benzonitrile A mixture of the title compound from Step 2 (100 mg, 0.29 mmol), the title compound from Step 4 (227 mg, 0.87 mmol), Na2CO3 (92 mg, 0.87 mmol), Pd(PPh3)4(67 mg, 0.06 mmol) in 1,4-dioxane (15 mL) and water (3 mL) in a sealed tube was degassed and stirred under nitrogen at 80° C. for 2.5 h. The reaction mixture was diluted with water, extracted with ethyl acetate and washed with brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative-HPLC to afford the title compound as a white solid (29.4 mg, 22%). 1H NMR (CD3OD, 400 MHz) δ 88.32 (d, 2H), 8.15 (s, 1H), 7.91 (s, 1H), 7.80-7.67 (m, 4H), 6.65 (S, 1H), 3.66-3.48 (m, 3H), 2.71 (s, 1H), 0.89-0.84 (d, 2H), 0.67-0.63 (d, 2H). LCMS (M+H)+ 444. |
[ N/A ]
Cyclopropyl-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyrimidin-2-yl]amine
Similarity: 1.00
[ 1218791-46-8 ]
N-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-47-9 ]
N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-47-9 ]
N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-48-0 ]
N-Butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ N/A ]
Cyclopropyl-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyrimidin-2-yl]amine
Similarity: 1.00
[ 1218791-46-8 ]
N-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-47-9 ]
N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-43-5 ]
N-(tert-Butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ 1218791-48-0 ]
N-Butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ 1218791-46-8 ]
N-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-47-9 ]
N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-43-5 ]
N-(tert-Butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ 1218791-48-0 ]
N-Butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ 1218791-46-8 ]
N-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-47-9 ]
N-Propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.96
[ 1218791-43-5 ]
N-(tert-Butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94
[ 1218791-48-0 ]
N-Butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.94